Destiny floats on AIM to pursue antibiotic resistance challenge

Oliver Haill WebFG News | 04 Sep, 2017 14:11 - Updated: 14:11 | | |

ep bacterias resistentesantibioticos
Bacterias resistentes a antibióticosEFSA

Destiny Pharma received a warm welcome when it became the second biotech to float in the UK this year, joining London's AIM junior market on Monday after raising £15.3m to develop its products aimed to tackle anti-microbial resistance.

Destiny, which saw its shares climb 26% by lunchtime on Monday to 197p from the initial public offer price of 157p, is focused on the development of novel anti-microbial drugs with a lead candidate poised to enter Phase IIb clinical trials.

With rising global concern over the dangers of life-threatening infections caused by antibiotic resistant bacteria -- such that it was the priority topic at the recent G20 summit in Germany -- the company is developing a drug platform with novel way of tackling the problem.

Destiny's XF-drug platform have been shown to rapidly kill bacteria by interfering with the properties of the surface of bacteria, resulting in the loss of vital components from the cell, and have been shown to kill bacteria in all growth states, including non-growing cultures which are resistant to a large number of antibiotics.

Unlike most antibiotics, XF drugs have demonstrated the ability to kill Staphylococcal bacteria -- such as that cause MRSA, food poisoning, cellulitis and toxic shock syndrome -- within biofilms.

The funds raised from the IPO, which was led by nominated adviser and broker Cantor Fitzgerald, will primarily be used to progress the lead drug candidate, XF-73, through a Phase IIb clinical trial in the prevention of post-surgical Staphylococcus aureus infections (including MRSA) over the next two years in the US, where it could potentially be fast-tracked to regulatory approval.

XF-73 has progressed through five Phase I/IIa clinical trials that have shown its rapid antibacterial action combined with evidence of a no/low resistance profile.

The Brighton-based outfit, which has market exclusivity including robust IP protection that potentially extends into 2030, has also agreed a framework agreement with China Medical Systems to develop and commercialise the company’s assets in China and certain other Asian countries, excluding Japan.

Chief executive Neil Clark, who is known to AIM investors as former boss of CeNeS Pharmaceuticals and is being guided at Destiny by Sir Nigel Rudd as chairman, said the funds are designed to see the lead drug candidate through the trials over the next two years. "If successful, XF-73 will then be ready for Phase III clinical development which will be a major value inflection point.

"XF-73 could be the first drug to be specifically labelled for a new US FDA sanctioned indication, namely the prevention of post-surgical infections; a market we believe to be worth a billion dollars in the US alone and growing.

More news

00:20 US close: Wall Street mixed ahead of Thanksgiving holiday

Wall Street finished mixed on Wednesday, following the record highs set the day before and amid lighter-than-usual trading volumes ahead of the Thanksgiving holiday on Thursday.

22 Nov Jefferies upgrades Kingfisher to 'buy', raises target price

Analysts at Jefferies upgraded home improvement products retailer Kingfisher (KGF) to 'buy' from its previous 'hold' rating on Wednesday, raising its target price from 310p to 400p along the way.

22 Nov Europe close: German stocks give back gains amid political impasse

Stocks ended the session modestly lower as traders waited for the release of the minutes of the US Federal Reserve's last rate-setting meeting in the evening and monitored the news-flow out of Germany, amid speculation that a 'grand coalition' between Germany's two main political parties, the centre-right CDU/CSU and the Socialist SPD, may yet be possible.

22 Nov Lebanon prime minister Hariri retracts resignation

Saad al-Hariri has revoked his resignation as Lebanon's prime minister, according to a local news report on Wednesday.

22 Nov Budget: Planning probe spooks builders, mixed reaction for stamp duty cut

A range of new housing policies were proposed by Chancellor Philip Hammond in his Budget statement, including more funds for smaller housebuilder, a probe into potential holding of land by major housebuilders and a stamp duty cut for first-time buyers.

22 Nov US open: Shares hold ground ahead of FOMC minutes

Wall Street is holding its ground following the record highs set the day before, albeit amid lighter than usual trading volumes ahead of the Thanksgiving Holiday on Thursday, with investors looking to the release of the minutes of the most recent meeting of the Federal Open Market Committee.

22 Nov London close: Stocks higher on UK budget

Shares closed higher on Wednesday as investors sifted through corporate releases as well as the Autumn Budget.

22 Nov FTSE 250 movers: Qinetiq boosted by Berenberg note as Thomas Cook tanks

The FTSE 250 index was up around 0.50% on the day in which Chancellor Philip Hammond revealed his budget for the upcoming year.

22 Nov Higher margins offset declining sales volumes at Cambria

Motor dealer Cambria Automobiles managed to successfully grow profit and revenue throughout the financial year, as per-unit profits counteracted a slide in sales volumes.

22 Nov First production at Texas asset transforms Pantheon Resources into full-cycle energy and power business

Oil and gas exploration firm Pantheon Resources announced "another year of progress" in its full-year results on Wednesday, as it completed the transition from a pure-play exploration company to a full-cycle energy and power business.